Pharmacological Therapy of Prozac

Article information

J Korean Med Assoc. 2008;51(3):273-282
Publication date (electronic) : 2008 March 31
doi : https://doi.org/10.5124/jkma.2008.51.3.273
Department of Psychiatry, Seoul National University College of Medicine, Korea. inkylyoo@snu.ac.kr, jeeyrhee@yahoo.com, junghyunlee1@yahoo.com

Abstract

Fluoxetine (Prozac®) has been reported to have equivalent efficacy and less side effects compared to the tricyclic antidepressants. It has become a new trend in the treatment of major depressive disorder since 1980's. Efficacy of fluoxetine has been shown not only in major depressive disorder, but also in obsessive compulsive disorder, panic disorder, bulimia nervosa, premenstrual dysphoric disorder, obesity, premature ejaculation, pain syndrome and other medical/psychiatric diseases. Fluoxetine is known to have more activating or stimulating effect than other selective serotonin reuptake inhibitors, which might be beneficial in treating the atypical feature of depression. It is also effective in diminishing appetite and carbohydrate craving. However, this effect is belived to be transient. Regarding the adverse effects, fluoxetine has the lower risk of discontinuation syndrome in comparison with other antidepressants, due to its long half-life. However, long half-life can be problematic when adverse effects become intolerable. Caution should be made when there is a possibility of drug interaction especially in the elderly. When it is prescribed to children and adolescents, monitoring for suicidal intent should be made.

References

1. Kelsey JE. In : Sadock BJ, Sadock VA, eds. Selective Serotonin Reuptake Inhibitor. Kaplan & Sadock's Comprehensive Textbook of Psychiatry 2005. 8th edth ed. Philadelphia: Lippincott Williams & Wilkins; 2887–2914.
2. Rosenbaum JF, Tollefson GD. In : Schatzberg AF, Nemeroff CB, eds. Fluoxetine. Essentials of Clinical Psychopharmacology 2006. 2nd edth ed. Washington: American Psychiatric Publishing, Inc.; 31–46.
3. Stokes PE, Holtz A. Fluoxetine Tenth Anniversary Update: The Progress Continues. Clin Ther 1997. 191135–1250.
4. Davis LL, Frazier EC, Williford RB, Newell JM. Long-Term Pharmacotherapy for Post-Traumatic Stress Disorder. CNS Drugs 2006. 20465–476.
5. Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in Bipolar Disorder: the Case for Caution. Bipolar Disord 2003. 5421–433.

Article information Continued